Shares of Puma Biotechnology, Inc. (NYSE:PBYI) reduced -8.42% to finish at $36.45 in last run as Puma Biotech (PBYI) presented that interim results ...
News
- Active Volatile Stocks- Puma Biotechnology (NYSE:PBYI), Baozun (NASDAQ:BZUN), Eli Lilly ...
- KU professor's research proves some science textbooks wrong
They wanted to share the research in Bioscience, because it's read by a broader variety of science-types, including high school science teachers.
- Puma Biotech (PBYI) Announces Encouraging Interim Data from PB272 Phase 2 Control Trial in ...
Puma Biotechnology, Inc. (NYSE: PBYI) announced that interim results from a Phase II clinical trial of Puma's investigational drug PB272 (neratinib) ...
- Puma Biotech (PBYI) Updates on PB272 NSABP FB-7 Phase 2; No Significant Difference Noted
Puma Biotechnology, Inc. (NYSE: PBYI) announced that a biomarker ... 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) that is ...
- Texas Innovations in Health Care: More Austin biotech companies go public, but hit stock turbulence
Editor's Note: This article is part of a special series produced jointly by the Business Journals in Austin, Dallas, Houston and San Antonio, highlighting ...